Publication: Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries
Issued Date
2020-07-06
Resource Type
ISSN
13499157
Other identifier(s)
2-s2.0-85087532226
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of radiation research. Vol.61, No.4 (2020), 608-615
Suggested Citation
Noriyuki Okonogi, Masaru Wakatsuki, Hideyuki Mizuno, Shigekazu Fukuda, Jianping Cao, Henry Kodrat, Fen Nee Lau, Miriam Joy Calaguas, Rey H. de Los Reyes, Yaowalak Chansilpa, A. F.M.Kamal Uddin, Tasbolat Adylkhanov, Chul Koo Cho, Uranchimeg Tsegmed, Nguyen Cong Hoang, Tatsuya Ohno, Takashi Nakano, Shingo Kato Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries. Journal of radiation research. Vol.61, No.4 (2020), 608-615. doi:10.1093/jrr/rraa025 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/57909
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Preliminary survey of 3D image-guided brachytherapy for cervical cancer at representative hospitals in Asian countries
Author(s)
Other Contributor(s)
Saitama Medical University International Medical Center
Graduate School of Medicine
National Institutes for Quantum and Radiological Science and Technology
QST Hospital
Jichi Medical University
Semey Medical University
St. Luke's Medical Center Quezon City
Jose R. Reyes Memorial Medical Center
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Korea Institute of Radiological and Medical Sciences
Faculty of Medicine, Siriraj Hospital, Mahidol University
Soochow University
National Cancer Council of Mongolia
Institut Kanser Negara
United Hospital Limited
National Cancer Hospital
Graduate School of Medicine
National Institutes for Quantum and Radiological Science and Technology
QST Hospital
Jichi Medical University
Semey Medical University
St. Luke's Medical Center Quezon City
Jose R. Reyes Memorial Medical Center
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Korea Institute of Radiological and Medical Sciences
Faculty of Medicine, Siriraj Hospital, Mahidol University
Soochow University
National Cancer Council of Mongolia
Institut Kanser Negara
United Hospital Limited
National Cancer Hospital
Abstract
© The Author(s) 2020. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. 3D image-guided brachytherapy (3D-IGBT) has become a standard therapy for cervical cancer. However, the use of 3D-IGBT is limited in East and Southeast Asia. This study aimed to clarify the current usage patterns of 3D-IGBT for cervical cancer in East and Southeast Asia. A questionnaire-based survey was performed in 11 countries within the framework of the Forum for Nuclear Cooperation in Asia. The questionnaire collected the treatment information of patients with cervical cancer who underwent 3D-IGBT. The cumulative external beam radiotherapy and 3D-IGBT doses were summarized and normalized to a biological equivalent dose of 2 Gy per fraction (EQD2) using a linear-quadratic model. Of the 11 institutions representing the participating countries, six (55%) responded to the questionnaire. Overall, data of 36 patients were collected from the six institutions. Twenty-one patients underwent whole-pelvic irradiation and 15 underwent whole-pelvic irradiation with central shielding. Patients received a median of four treatment sessions of 3D-IGBT (range, 2-6). All 3D-IGBT sessions were computed tomography (CT)-based and not magnetic resonance image-based. The median doses to the high-risk clinical target volume D90, bladder D2cc, rectum D2cc and sigmoid colon D2cc were 80.9 Gy EQD2 (range, 58.9-105.9), 77.7 Gy EQD2 (range, 56.9-99.1), 68.0 Gy EQD2 (range, 48.6-90.7) and 62.0 Gy EQD2 (range, 39.6-83.7), respectively. This study elucidated the current patterns of 3D-IGBT for the treatment of cervical cancer in East and Southeast Asia. The results indicate the feasibility of observational studies of CT-based 3D-IGBT for cervical cancer in these countries.